Many previous studies have sought to determine whether there is a true link between ATA therapy in IBD and development of lymphoma
Patients on azathioprine are immunosuppressed, so they are at a higher risk of infections
Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis Clin Gastroenterol Hepatol
The increased risk of
76), which decreased to 0
Whether the risk of lymphoma is increased by immunosuppressive treatment with azathioprine, 6-mercaptopurine or infliximab is a common concern among patients
The malignancy risk associated with MMF or azathioprine use in patients with ILD remains unknown
A case-control study shows an increased risk for lymphoma, consistent with previous studies, but no overall increase in the risk for cancer in patients with
Our data suggest an approximate fourfold increased risk of lymphoma in IBD patients treated with azathioprine/6-MP
Further analysis of these findings suggested an increased risk of lymphoma of one case per 1000 patient years of azathioprine treatment
Azathioprine and 6-mercaptopurine (6-MP) remain important agents for the induction and maintenance of remission in inflammatory bowel disease, and the prevention of postoperative Crohn’s disease (Gastroenterology 2004;127:723–729)
In the absence of immunosuppressive therapies, patients with infammatory bowel disease (IBD) probably have, at most, only a very slightly increased risk of Iatrogenic immunosuppression is a strong risk factor for non-Hodgkin lymphoma (NHL) but the dose-related association between individual immunosuppressive agents and NHL risk is unknown
A case-control study evaluating azathioprine exposure in multiple sclerosis patients with and without cancer also found no association
Tell your doctor if you have or have ever had This review found that individuals with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine have four times the risk of developing lymphoma compared with the general population
(2005) performed a meta-analysis using six published cohort studies on patients with inflammatory bowel disease, and found a meta-relative risk for non-Hodgkin lymphoma associated with the use of azathioprine of 4
Many of these lymphomas are associated with Epstein-Barr virus (EBV), which might be reactivated under immunosuppression
The data suggest an approximate fourfold increased risk of lymphoma in IBD patients treated with azathioprine/6-MP, which could be a result of the medications, the severity of the underlying disease, or a combination of the two
28703
Similarly, an inherent risk of cancer (particularly lymphoma) in conditions such as IBD and rheumatoid arthritis has been identified as a possible confounder in the assessment of the potential association of azathioprine use and neoplasia development (Aithal and Mansfield 2001; Kandiel et al
Following absorption, their metabolite - 6 Dotlić S, et al
Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease
In IBD, studies suggest a small increased risk of lymphoma and protection against colorectal cancer, but the
Two large prospective epidemiological studies reported high incidences of non-Hodgkin lymphoma, skin cancer (squamous-cell carcinoma), connective-tissue tumors (mesenchymal tumors), and cancer of the liver, bile ducts, or gallbladder (hepatobiliary carcinoma) in kidney-transplant patients, who are
This is not an estimate of the half-life of azathioprine itself, but is the decay rate for all 35 S-containing metabolites of the drug
Prospective follow-up for a median of 35 months of a French cohort of 19 486 patients with inflammatory bowel disease showed a nearly 4-fold increase in the risk of lymphoma in patients exposed to azathioprine or mercaptopurine (relative risk 3
The increased risk of malignancy led to the following boxed label on the FDA-approved drug label for azathioprine: Azathioprine may cause a rare type of lymphoma (cancer) of the liver, spleen, and bone marrow that can be fatal